IL107843A0 - Aminomethylene substituted non-aromatic heterocycles - Google Patents

Aminomethylene substituted non-aromatic heterocycles

Info

Publication number
IL107843A0
IL107843A0 IL10784393A IL10784393A IL107843A0 IL 107843 A0 IL107843 A0 IL 107843A0 IL 10784393 A IL10784393 A IL 10784393A IL 10784393 A IL10784393 A IL 10784393A IL 107843 A0 IL107843 A0 IL 107843A0
Authority
IL
Israel
Prior art keywords
aromatic heterocycles
substituted non
compounds
aminomethylene
aminomethylene substituted
Prior art date
Application number
IL10784393A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL107843A0 publication Critical patent/IL107843A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL10784393A 1992-12-10 1993-12-02 Aminomethylene substituted non-aromatic heterocycles IL107843A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98865392A 1992-12-10 1992-12-10

Publications (1)

Publication Number Publication Date
IL107843A0 true IL107843A0 (en) 1994-04-12

Family

ID=25534364

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10784393A IL107843A0 (en) 1992-12-10 1993-12-02 Aminomethylene substituted non-aromatic heterocycles

Country Status (15)

Country Link
EP (2) EP0675886B1 (zh)
JP (2) JP2722279B2 (zh)
CN (1) CN1092771A (zh)
AT (1) ATE194340T1 (zh)
AU (1) AU5169693A (zh)
CA (1) CA2150123C (zh)
DE (1) DE69328975T2 (zh)
DK (1) DK0675886T3 (zh)
ES (1) ES2147759T3 (zh)
FI (1) FI935529A (zh)
GR (1) GR3034329T3 (zh)
IL (1) IL107843A0 (zh)
MX (1) MX9307810A (zh)
PT (1) PT675886E (zh)
WO (1) WO1994013663A1 (zh)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
JP2963200B2 (ja) * 1993-09-17 1999-10-12 ファイザー・インク. ヘテロアリールアミノおよびヘテロアリールスルホンアミド置換3−ベンジルアミノメチルピペリジン類および関連化合物
IS4208A (is) * 1993-09-22 1995-03-23 Glaxo Group Limited 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður
EP0653208A3 (en) * 1993-11-17 1995-10-11 Pfizer Substance P antagonists for the treatment or prevention of sunburn.
EP0659409A3 (en) * 1993-11-23 1995-08-09 Pfizer Substance P antagonists for the inhibition of angiogenesis.
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
GB9505692D0 (en) * 1995-03-21 1995-05-10 Glaxo Group Ltd Chemical compounds
AU696948B2 (en) * 1995-03-27 1998-09-24 Hisamitsu Pharmaceutical Co., Inc. Piperidine derivatives
DK0840732T3 (da) * 1995-07-07 2001-04-17 Pfizer Substituerede benzolactamforbindelser som substans P-antagonister
US6288225B1 (en) 1996-05-09 2001-09-11 Pfizer Inc Substituted benzolactam compounds as substance P antagonists
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
DE60007625T2 (de) * 1999-05-06 2004-11-18 Pfizer Products Inc., Groton Substituierte benzolactamverbindungen
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のnk−1レセプターアンタゴニスト及びエレトリプタン
US7119207B2 (en) * 2000-04-10 2006-10-10 Pfizer Inc Benzoamide piperidine containing compounds and related compounds
CA2405518C (en) * 2000-04-19 2009-07-07 Neurotech Co., Ltd. Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system
US6573402B1 (en) 2000-04-20 2003-06-03 Neurotech Co., Ltd. Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
WO2002028853A1 (fr) * 2000-10-02 2002-04-11 Tanabe Seiyaku Co., Ltd. Compose de benzylamine, son procede de production et produit intermediaire correspondant
JP2004529110A (ja) 2001-03-06 2004-09-24 アストラゼネカ アクチボラグ 脈管損傷活性を有するインドール誘導体
KR100545745B1 (ko) 2002-06-19 2006-01-24 주식회사 뉴로테크 테트라플루오로벤질 유도체 및 이를 함유하는 급성 및퇴행성 뇌신경계 질환의 예방 및 치료용 약학적 조성물
GEP20094640B (en) 2004-07-15 2009-03-10 Bristol Myers Squibb Co Aryl-and heteroaryl-substituted tetrahydro isoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
EP1904069B1 (en) 2005-07-15 2018-06-13 Albany Molecular Research, Inc. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
KR101335029B1 (ko) 2006-04-13 2013-11-28 주식회사 지엔티파마 세포 손상 및 염증 질환의 치료 또는 예방용 약학 조성물
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
DK2805945T3 (da) 2007-01-10 2019-07-15 Msd Italia Srl Amid-substituerede indazoler som poly(adp-ribose)polymerase- (parp) hæmmere
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
EP2170076B1 (en) 2007-06-27 2016-05-18 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
KR100852962B1 (ko) 2007-11-12 2008-08-20 주식회사 뉴로테크 2-하이드록시-5-페닐알킬아미노벤조산 유도체 및 이의 염의제조방법
WO2009111354A2 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
KR101204108B1 (ko) * 2009-02-09 2012-11-22 주식회사 지엔티파마 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme INHIBITORS OF AKT ACTIVITY
MX2011011907A (es) 2009-05-12 2012-01-20 Albany Molecular Res Inc 7-([1,2,4,]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2, 3,4-tetrahidroisoquinolina y uso de la misma.
EP2429295B1 (en) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
EP2488028B1 (en) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
EP3330377A1 (en) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
CA2807307C (en) 2010-08-17 2021-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
CN103732592A (zh) 2011-04-21 2014-04-16 默沙东公司 胰岛素样生长因子-1受体抑制剂
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
CN105050598B (zh) 2012-09-28 2018-04-27 默沙东公司 作为erk抑制剂的新型化合物
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
HUE035662T2 (en) 2012-11-28 2018-05-28 Merck Sharp & Dohme Compositions and procedures for treating cancer
RU2690663C2 (ru) 2012-12-20 2019-06-05 Мерк Шарп И Доум Корп. Замещенные имидазопиридины в качестве ингибиторов hdm2
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CN109174181B (zh) * 2018-08-10 2021-05-25 华东师范大学 一种负载双功能离子液体介孔聚合物的制备及其应用
AU2019412533A1 (en) * 2018-12-28 2021-07-15 Gnt Pharma Co., Ltd. Compositions and methods for treating neurodegenerative disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
UA41251C2 (uk) * 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
JPH0794439B2 (ja) * 1990-05-31 1995-10-11 フアイザー・インコーポレイテツド 置換ピペリジンの製造法
DK0540526T3 (da) * 1990-07-23 1995-04-18 Pfizer Quinuclidinderivater
HUT68667A (en) * 1990-09-28 1995-07-28 Pfizer Fused ring analogs of nitrogen containing nonaromatic heterocycles
US5242930A (en) * 1991-02-11 1993-09-07 Merck Sharp & Dohme Ltd. Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
CZ289960B6 (cs) * 1991-03-26 2002-05-15 Pfizer Inc. Způsob přípravy substituovaných piperidinů
DE69232334T2 (de) * 1991-05-22 2002-11-14 Pfizer Substituierte 3-aminochinuclidine
TW202432B (zh) * 1991-06-21 1993-03-21 Pfizer

Also Published As

Publication number Publication date
ATE194340T1 (de) 2000-07-15
JP2722279B2 (ja) 1998-03-04
DE69328975D1 (de) 2000-08-10
FI935529A (fi) 1994-06-11
EP0806423A1 (en) 1997-11-12
CA2150123C (en) 2004-12-07
EP0675886B1 (en) 2000-07-05
WO1994013663A1 (en) 1994-06-23
DE69328975T2 (de) 2000-11-09
CN1092771A (zh) 1994-09-28
ES2147759T3 (es) 2000-10-01
JPH1095780A (ja) 1998-04-14
CA2150123A1 (en) 1994-06-23
PT675886E (pt) 2000-12-29
DK0675886T3 (da) 2000-09-18
GR3034329T3 (en) 2000-12-29
JP3165401B2 (ja) 2001-05-14
FI935529A0 (fi) 1993-12-09
MX9307810A (es) 1994-07-29
EP0675886A1 (en) 1995-10-11
AU5169693A (en) 1994-07-04
JPH07509490A (ja) 1995-10-19

Similar Documents

Publication Publication Date Title
IL107843A0 (en) Aminomethylene substituted non-aromatic heterocycles
IL106670A0 (en) Substituted benzylamino nitrogen containing non-aromatic heterocycles
CA2134964A1 (en) Bridged Aza-Bicyclic Derivatives as Substance P Antagonists
HU9401974D0 (en) New intermediates for producing 9-[(substituted glicyl)-amido]-6-demetyl-6-deoxy-tetracyclines and pharmaceutical compositions containing them
IL99525A0 (en) Fused ring analogs of nitrogen containing nonaromatic heterocycles
WO1993000330A3 (en) Azanorbornane derivatives
IL108769A0 (en) Spirocyclic piperidine derivatives
AU1889392A (en) Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
SG47520A1 (en) New method for the production of 9-amino-6-demethyl-6-deoxytetracycline
IL119118A0 (en) 9-Ú(Haloacyl) amido¾-7- (substituted)-6- demethyl-6-deoxytetracycline intermediates
EP0551844A3 (zh)
ES2087813A1 (es) Heterociclos no-aromaticos que contienen nitrogeno bencilamino substituidos.
EP0928792A3 (en) Bicyclic(3.1.0)hexanes and related compounds
CA2171972A1 (en) Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds
ES2097688A1 (es) Hexahidroazepinonas y tetrahidrobenzazepinonas sustituidas.